A Phase I/IIa, Open-label, Multicenter Study of the Safety and Efficacy of CHO-H01 As a Single Agent/Combined with Lenalidomide to Subjects with Refractory or Relapsed Non-Hodgkin's Lymphoma
Latest Information Update: 21 Mar 2025
At a glance
- Drugs CHO H01 (Primary) ; Lenalidomide (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors CHO Pharma
Most Recent Events
- 18 Mar 2025 Planned End Date changed from 1 Jun 2026 to 23 Dec 2026.
- 18 Mar 2025 Planned primary completion date changed from 1 Dec 2025 to 23 Dec 2026.
- 24 Jul 2024 Planned number of patients changed from 11 to 37.